Finnish Children´s Protracted Cough
A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted Cough
Tampere University Hospital
100 participants
Dec 22, 2025
INTERVENTIONAL
Conditions
Summary
Prolonged cough lasting more than four weeks is common in children, but the best treatment is often unclear when no underlying disease can be found. This study aims to find out whether commonly used treatments help children with prolonged cough more effectively than placebo. Children who take part will first undergo standard medical examinations, including lung function tests and a chest X-ray, to look for the cause of the cough. If no specific cause is found, the child may enter the study. Children with a dry cough will be randomly assigned to receive either an inhaled corticosteroid (fluticasone) or a placebo inhaler for two months. Children with a wet or productive cough will be randomly assigned to receive either an oral antibiotic (amoxicillin-clavulanic acid) or a placebo medicine for 14 days. Neither the families nor the researchers will know which treatment the child receives during the study. The main goal is to determine whether these treatments significantly reduce or stop the cough compared with placebo. The results will help improve treatment recommendations for children with prolonged cough and avoid unnecessary medication use. Participation is voluntary, and parents provide written informed consent for their child.
Eligibility
Inclusion Criteria8
- Prolonged cough lasting continuously for more than 4 weeks
- No chronic disease requiring continuous medication (i.e. a generally healthy child)
- No previous physician-diagnosed condition associated with prolonged cough episodes
- No physician-identified symptoms or findings suggestive of an underlying disease
- No prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products (fluticasone or amoxicillin-clavulanic acid)
- No simultaneous participation in another clinical drug trial
- Parents/guardians have sufficient spoken and written Finnish language proficiency
- Written, voluntary informed consent provided by a parent or legal guardian
Exclusion Criteria8
- Children with symptoms or findings suggestive of an underlying cause of cough, including:
- A previously physician-diagnosed disease associated with prolonged cough
- Clinical examination or history at the study visit raising suspicion of a disease associated with prolonged cough (positive "cough pointers")
- Abnormal lung function test
- Abnormal chest X-ray (peribronchial markings are permitted)
- Prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products
- Simultaneous participation in another clinical drug trial
- Prolonged cough that has resolved spontaneously prior to the study visit
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Fluticasone propionate 125 micrograms (Trade name: Flixotide Evohaler) Administration (all ages): 125 micrograms (1 puff) twice daily via spacer Duration of treatment: 2 months
Amoxicillin-clavulanic acid oral suspension 80/11.4 mg/ml Cream-white, sweet-tasting suspension Administration: Oral, weight-adjusted dosing 50 mg/kg/day divided into two equal doses Duration of treatment: 2 weeks
Evohaler training inhaler 1. puff twice daily via spacer Duration of treatment: 2. months
Syrspend oral suspension base thickened with microcrystalline cellulose, without active pharmaceutical ingredient, administered with the same weight-adjusted regimen. Duration of treatment: 2 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07582549